Astellas Receives European Commission Approval for First-in-Class EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney DiseaseGlobeNewsWire • 08/19/21
FibroGen Announces Retirement of Pat Cotroneo and Appointment of Juan Graham as Chief Financial OfficerGlobeNewsWire • 08/16/21
FibroGen Shares Are Trading Lower As FDA Shoots Down Roxadustat Application, Asks For Additional TrialBenzinga • 08/11/21
FibroGen Receives Complete Response Letter from the FDA for Roxadustat for Anemia of Chronic Kidney DiseaseGlobeNewsWire • 08/11/21
FibroGen, Inc. (FGEN) CEO Enrique Conterno on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/10/21
FibroGen (FGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 ReleaseZacks Investment Research • 07/29/21
Eluminex Biosciences Exclusively Licenses FibroGen's Biosynthetic Cornea Technology and Recombinant Collagen III PlatformGlobeNewsWire • 07/19/21
AstraZeneca says FDA advisory committee won't support CKD treatment for approval, partner FibroGen stock plungesMarket Watch • 07/16/21
FibroGen Staring At Multi-Year Lows Following Adverse Roxadustat AdCom Verdict; How Hard Will The Stock Likely Fall?Benzinga • 07/16/21
FibroGen Announces Outcome of FDA Advisory Committee Review of Roxadustat for Treatment of Anemia of Chronic Kidney DiseaseGlobeNewsWire • 07/15/21